NOAs | Class | Indications | Dosage | Time to peak plasma concentration | Half life | Routes of elimination | Monitoring of coagulation |
---|---|---|---|---|---|---|---|
Dabigatran etexilate | Direct thrombin inhibitor | Prevention of cerebrovascular complications in non-valvular atrial fibrillation; hip and knee replacement surgery; venous thromboembolism prophylaxis and management | 110 mg- 150 mg twice daily | 2–4 h | 12–14 h; 14–17 h in elderly; 15–18 h in moderate renal impairment; up to 28 h in advanced renal impairment | 80 % renal, 20 % hepatic | Not needed |
Rivaroxaban | Direct inhibitor of factor Xa | Prevention of cerebrovascular complications in non-valvular atrial fibrillation; venous thromboembolism prophylaxis and management | 20 mg daily | 2.5–4 h | 5–10 h; 12–13 h in patients > 75 years | 66 % renal, 28 % in feces | Not needed |
Apixaban | Direct inhibitor of factor Xa | Prevention of cerebrovascular complications in non-valvular atrial fibrillation; venous thromboembolism prophylaxis and management | 5 mg twice daily | 1–3 h | 10–14 h | 25 % renal, 55 % intestinal, remnant hepatic | Not needed |